Sana lays off 15%, trims pipeline to keep funding flowing to off-the-shelf CAR-Ts

So-called off-the-shelf cell therapies may be one of the hotter areas of biotech right now, but that doesn’t mean these companies are immune to the wave of layoffs spreading across the sector. The latest is Sana Biotechnology, which is letting go of 15% of its workforce and discontinuing development of a heart failure drug.